Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance
Authors
Keywords
-
Journal
Expert Review of Anticancer Therapy
Volume 16, Issue 6, Pages 615-623
Publisher
Informa UK Limited
Online
2016-04-23
DOI
10.1080/14737140.2016.1182427
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 1295PEFFICACY AND SAFETY OF CERITINIB IN PATIENTS (PTS) WITH ADVANCED ANAPLASTIC LYMPHOMA KINASE (ALK)-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC): AN UPDATE OF ASCEND-1
- (2017) E. Felip et al. ANNALS OF ONCOLOGY
- First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors
- (2016) Tianhong Li et al. Journal of Hematology & Oncology
- Activity and safety of ceritinib in patients with ALK -rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
- (2016) Dong-Wan Kim et al. LANCET ONCOLOGY
- 111P * CERITINIB TREATMENT OF PATIENTS (PTS) WITH ALK-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES: ASCEND-1 TRIAL EXPERIENCE
- (2015) D.- W. Kim et al. ANNALS OF ONCOLOGY
- A Functional Landscape of Resistance to ALK Inhibition in Lung Cancer
- (2015) Frederick H. Wilson et al. CANCER CELL
- PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models
- (2015) Helen Y. Zou et al. CANCER CELL
- In vivoimaging models of bone and brain metastases and pleural carcinomatosis with a novel humanEML4-ALKlung cancer cell line
- (2015) Shigeki Nanjo et al. CANCER SCIENCE
- Safety of cranial radiotherapy concurrent with tyrosine kinase inhibitors in non-small cell lung cancer patients: A systematic review
- (2015) Lizza E.L. Hendriks et al. CANCER TREATMENT REVIEWS
- Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib
- (2015) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- FDA Approval: Ceritinib for the Treatment of Metastatic Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
- (2015) S. Khozin et al. CLINICAL CANCER RESEARCH
- Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine
- (2015) R. Katayama et al. CLINICAL CANCER RESEARCH
- Entrectinib: a potent new TRK, ROS1, and ALK inhibitor
- (2015) Christian Rolfo et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Are We Systematically Under-Dosing Patients With Fluorouracil?
- (2015) Kalpesh Patel et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases
- (2015) Daniel B. Costa et al. JOURNAL OF CLINICAL ONCOLOGY
- CSF Concentration of Crizotinib in Two ALK-Positive Non–Small-Cell Lung Cancer Patients with CNS Metastases Deriving Clinical Benefit from Treatment
- (2015) Giulio Metro et al. Journal of Thoracic Oncology
- Cystic Brain Metastases in NSCLC Harboring the EML4-ALK Translocation after Treatment with Crizotinib
- (2015) Christine Saraceni et al. Journal of Thoracic Oncology
- Alectinib Salvages CNS Relapses in ALK-Positive Lung Cancer Patients Previously Treated with Crizotinib and Ceritinib
- (2015) Justin F. Gainor et al. Journal of Thoracic Oncology
- Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non–Small-Cell Lung Cancer or Other Tumors
- (2015) Makoto Nishio et al. Journal of Thoracic Oncology
- Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK -positive NSCLC: Implications for disease assessment and management
- (2015) Sai-Hong Ignatius Ou et al. LUNG CANCER
- Future options for ALK-positive non-small cell lung cancer
- (2015) Daniela Iacono et al. LUNG CANCER
- Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers
- (2015) Deepa Rangachari et al. LUNG CANCER
- Unsanctifying the sanctuary: challenges and opportunities with brain metastases
- (2015) S. Puhalla et al. NEURO-ONCOLOGY
- Does lung cancer mutation status and targeted therapy predict for outcomes and local control in the setting of brain metastases treated with radiation?
- (2015) Tony J. C. Wang et al. NEURO-ONCOLOGY
- Alectinib Induces a Durable (>15 Months) Complete Response in an ALK-Positive Non-Small Cell Lung Cancer Patient Who Progressed on Crizotinib With Diffuse Leptomeningeal Carcinomatosis
- (2015) S.-H. I. Ou et al. ONCOLOGIST
- Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2)
- (2015) Anita Kort et al. PHARMACOLOGICAL RESEARCH
- Crizotinib-Induced Abnormal Signal Processing in the Retina
- (2015) Toshiyuki Ishii et al. PLoS One
- PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations
- (2015) Helen Y. Zou et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden
- (2015) Annie Guérin et al. JOURNAL OF MEDICAL ECONOMICS
- Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases
- (2014) Tatsushi Kodama et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance
- (2014) Tatsushi Kodama et al. CANCER LETTERS
- Abstract 5655: AP26113 possesses pan-inhibitory activity versus crizotinib-resistant ALK mutants and oncogenic ROS1 fusions.
- (2014) Rachel M. Squillace et al. CANCER RESEARCH
- Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases
- (2014) Stefan Zimmermann et al. CANCER TREATMENT REVIEWS
- Molecular Pathways: Resistance to Kinase Inhibitors and Implications for Therapeutic Strategies
- (2014) C. M. Lovly et al. CLINICAL CANCER RESEARCH
- Prolonged Survival of Patients With Non–Small-Cell Lung Cancer With Leptomeningeal Carcinomatosis in the Modern Treatment Era
- (2014) Jonathan W. Riess et al. Clinical Lung Cancer
- Prospective screening for ALK: Clinical features and outcome according to ALK status
- (2014) Vincent Fallet et al. EUROPEAN JOURNAL OF CANCER
- Cystic Brain Metastasis in Non–Small-Cell Lung Cancer With ALK Rearrangement
- (2014) Hidetoshi Hayashi et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations
- (2014) Ted W. Johnson et al. JOURNAL OF MEDICINAL CHEMISTRY
- LDK378 Compassionate Use for Treating Carcinomatous Meningitis in an ALK Translocated Non–Small-Cell Lung Cancer
- (2014) Jennifer Arrondeau et al. Journal of Thoracic Oncology
- Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
- (2014) Shirish M Gadgeel et al. LANCET ONCOLOGY
- Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK–Positive Anaplastic Large Cell Lymphoma
- (2014) M. Ceccon et al. MOLECULAR CANCER RESEARCH
- Alectinib Shows Potent Antitumor Activity against RET-Rearranged Non-Small Cell Lung Cancer
- (2014) T. Kodama et al. MOLECULAR CANCER THERAPEUTICS
- Acquired resistance to TKIs in solid tumours: learning from lung cancer
- (2014) D. Ross Camidge et al. Nature Reviews Clinical Oncology
- Current approaches to the treatment of metastatic brain tumours
- (2014) Taofeek K. Owonikoko et al. Nature Reviews Clinical Oncology
- Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases
- (2014) K. S. Mak et al. NEURO-ONCOLOGY
- Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study
- (2014) Aki Morikawa et al. NEURO-ONCOLOGY
- Incidence of brain metastasis at initial presentation of lung cancer
- (2014) J. Lee Villano et al. NEURO-ONCOLOGY
- Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Crizotinib Reduces the Rate of Dark Adaptation in the Rat Retina Independent of ALK Inhibition
- (2014) Chang-Ning Liu et al. TOXICOLOGICAL SCIENCES
- The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer
- (2014) L. Friboulet et al. Cancer Discovery
- ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer
- (2013) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- A Clinical Model for Identifying Radiosensitive Tumor Genotypes in Non-Small Cell Lung Cancer
- (2013) K. L. Johung et al. CLINICAL CANCER RESEARCH
- The role of systemic and targeted therapies in brain metastases
- (2013) Enrico Franceschi et al. Expert Review of Anticancer Therapy
- Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar
- (2013) Seng Chuan Tang et al. INTERNATIONAL JOURNAL OF CANCER
- Use of Statins and the Risk of Death in Patients With Prostate Cancer
- (2013) Oriana Yu et al. JOURNAL OF CLINICAL ONCOLOGY
- Leptomeningeal Carcinomatosis in Non–Small-Cell Lung Cancer Patients: Impact on Survival and Correlated Prognostic Factors
- (2013) Su Jin Lee et al. Journal of Thoracic Oncology
- High-Dose Crizotinib for Brain Metastases Refractory to Standard-Dose Crizotinib
- (2013) Young Hak Kim et al. Journal of Thoracic Oncology
- Effective Crizotinib Schedule for Brain Metastases in ALK Rearrangement Metastatic Non–Small-Cell Lung Cancer
- (2013) Nir Peled et al. Journal of Thoracic Oncology
- The Central Nervous System as a Sanctuary Site in ALK-Positive Non–Small-Cell Lung Cancer
- (2013) Justin F. Gainor et al. Journal of Thoracic Oncology
- CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study
- (2013) Takashi Seto et al. LANCET ONCOLOGY
- ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer
- (2013) Matthias Preusser et al. LUNG CANCER
- ALK Inhibitor PF02341066 (Crizotinib) Increases Sensitivity to Radiation in Non-Small Cell Lung Cancer Expressing EML4-ALK
- (2013) Y. Sun et al. MOLECULAR CANCER THERAPEUTICS
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of clinical characteristics between patients with ALK-positive and EGFR-positive lung adenocarcinoma
- (2013) Hyo Jae Kang et al. RESPIRATORY MEDICINE
- Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer
- (2012) Robert C. Doebele et al. CANCER
- Disease Flare After Treatment Discontinuation in a Patient With EML4-ALK Lung Cancer and Acquired Resistance to Crizotinib
- (2012) Oana Pop et al. Journal of Thoracic Oncology
- Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer
- (2012) Andrew J. Weickhardt et al. Journal of Thoracic Oncology
- High-Dose Pemetrexed in Combination with High-Dose Crizotinib for the Treatment of Refractory CNS Metastases in ALK-Rearranged Non–Small-Cell Lung Cancer
- (2012) Leena Gandhi et al. Journal of Thoracic Oncology
- Adenocarcinoma of the lung with miliary brain and pulmonary metastases with echinoderm microtubule-associated protein like 4-anaplastic lymphoma kinase translocation treated with crizotinib: A case report
- (2012) Alexander T. Falk et al. LUNG CANCER
- Crizotinib for the Treatment of ALK -Rearranged Non-Small Cell Lung Cancer: A Success Story to Usher in the Second Decade of Molecular Targeted Therapy in Oncology
- (2012) Sai-Hong Ignatius Ou et al. ONCOLOGIST
- CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant
- (2011) Hiroshi Sakamoto et al. CANCER CELL
- Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors
- (2011) C. M. Lovly et al. CANCER RESEARCH
- CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
- (2011) Daniel B. Costa et al. JOURNAL OF CLINICAL ONCOLOGY
- Leptomeningeal Metastasis from Non-small Cell Lung Cancer: Survival and the Impact of Whole Brain Radiotherapy
- (2011) Patrick G. Morris et al. Journal of Thoracic Oncology
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
- (2011) Alice T Shaw et al. LANCET ONCOLOGY
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
- (2009) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictors of Competing Mortality in Advanced Head and Neck Cancer
- (2009) Loren K. Mell et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now